MCID: BPL002
MIFTS: 50

Bipolar I Disorder

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Bipolar I Disorder

MalaCards integrated aliases for Bipolar I Disorder:

Name: Bipolar I Disorder 12 77 15 74

Classifications:



External Ids:

Disease Ontology 12 DOID:14042
ICD9CM 36 296.50
SNOMED-CT 69 49468007

Summaries for Bipolar I Disorder

Disease Ontology : 12 A bipolar disorder that is characterized by at least one manic or mixed episode.

MalaCards based summary : Bipolar I Disorder is related to bipolar disorder and depression. An important gene associated with Bipolar I Disorder is BDNF (Brain Derived Neurotrophic Factor), and among its related pathways/superpathways are G-Beta Gamma Signaling and Neuroscience. The drugs Dopamine and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include brain, amygdala and cortex, and related phenotypes are behavior/neurological and muscle

Wikipedia : 77 Bipolar I disorder (BD-I; pronounced "type one bipolar disorder") is a bipolar spectrum disorder... more...

Related Diseases for Bipolar I Disorder

Diseases in the Bipolar Disorder family:

Bipolar Ll Disorder Bipolar I Disorder

Diseases related to Bipolar I Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 99)
# Related Disease Score Top Affiliating Genes
1 bipolar disorder 30.9 BDNF COMT DAO DRD2 DTNBP1 HTR1A
2 depression 30.4 BDNF HTR1A HTR2A HTR2C SLC6A4
3 sexual disorder 30.2 HTR1A SLC6A4
4 tardive dyskinesia 30.2 COMT DRD2 HTR2A
5 schizoaffective disorder 30.0 BDNF COMT DRD2 DTNBP1 HTR2A SLC6A4
6 conduct disorder 30.0 COMT DRD2 SLC6A4
7 neuroleptic malignant syndrome 29.9 DRD2 HTR1A
8 substance abuse 29.9 BDNF COMT DRD2 SLC6A4
9 anxiety 29.8 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
10 autism 29.8 BDNF HTR1A HTR2A SLC6A4
11 panic disorder 29.7 COMT HTR1A HTR2A SLC6A4
12 major depressive disorder 29.5 BDNF COMT DRD2 HTR1A HTR2A HTR2C
13 personality disorder 29.4 BDNF COMT DRD2 HTR1A HTR2A HTR2C
14 borderline personality disorder 29.3 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
15 mental depression 29.3 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
16 attention deficit-hyperactivity disorder 29.2 BDNF COMT DRD2 HTR1A HTR2A HTR2C
17 obsessive-compulsive disorder 29.2 BDNF COMT DRD2 HTR1A HTR2A HTR2C
18 schizophrenia 29.1 BDNF COMT DAO DRD2 DTNBP1 HTR1A
19 mood disorder 28.9 BDNF COMT DRD2 HTR1A HTR2A HTR2C
20 alcohol dependence 28.8 BDNF COMT DRD2 HTR1A HTR2A HTR2C
21 disease of mental health 28.2 BDNF COMT DRD2 DTNBP1 HTR1A HTR2A
22 psychotic disorder 27.7 BDNF COMT DAO DRD2 DTNBP1 HTR1A
23 tic disorder 10.4 DRD2 HTR2A
24 polysubstance abuse 10.3 COMT DRD2
25 alcohol-induced mental disorder 10.3 DRD2 SLC6A4
26 atypical depressive disorder 10.3 HTR2A SLC6A4
27 heroin dependence 10.3 BDNF DRD2
28 traumatic brain injury 10.2 BDNF COMT DRD2
29 postpartum depression 10.2 BDNF COMT SLC6A4
30 brain injury 10.2 BDNF COMT DRD2
31 dysthymic disorder 10.2 HTR2A SLC6A4
32 oppositional defiant disorder 10.2 COMT DRD2 SLC6A4
33 schizoid personality disorder 10.2 HTR1A HTR2A
34 specific developmental disorder 10.2 BDNF COMT SLC6A4
35 early-onset schizophrenia 10.2 BDNF DRD2 HTR2A
36 antisocial personality disorder 10.2 COMT DRD2 SLC6A4
37 hypoactive sexual desire disorder 10.2 HTR1A HTR2A
38 kleptomania 10.2 HTR1A SLC6A4
39 drug dependence 10.2 BDNF DRD2 SLC6A4
40 gilles de la tourette syndrome 10.2 BDNF COMT DRD2
41 substance dependence 10.2 BDNF DRD2 SLC6A4
42 cannabis dependence 10.2 COMT NRG1
43 phobic disorder 10.2 COMT HTR1A SLC6A4
44 fibromyalgia 10.2 COMT HTR2A SLC6A4
45 alcoholic psychosis 10.2 DRD2 HTR2A SLC6A4
46 brunner syndrome 10.2 COMT HTR1A SLC6A4
47 pathological gambling 10.2 DRD2 HTR2A SLC6A4
48 schizophreniform disorder 10.2 COMT DRD2 NRG1
49 social phobia 10.2 DRD2 HTR1A SLC6A4
50 substance-induced psychosis 10.1 DRD2 HTR1A HTR2A

Graphical network of the top 20 diseases related to Bipolar I Disorder:



Diseases related to Bipolar I Disorder

Symptoms & Phenotypes for Bipolar I Disorder

MGI Mouse Phenotypes related to Bipolar I Disorder:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.93 BDNF COMT DAO DRD2 DTNBP1 EGR3
2 muscle MP:0005369 9.43 DRD2 DTNBP1 EGR3 HTR2A HTR2C SLC6A4
3 nervous system MP:0003631 9.36 BDNF COMT DAO DRD2 DTNBP1 EGR3

Drugs & Therapeutics for Bipolar I Disorder

Drugs for Bipolar I Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 156)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
2
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129722-12-9 60795
3
Lithium carbonate Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 554-13-2
4
Ziprasidone Approved Phase 4,Phase 3,Phase 2 146939-27-7 60854
5
Oxcarbazepine Approved Phase 4 28721-07-5 34312
6
Coal tar Approved Phase 4 8007-45-2
7
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 99-66-1 3121
8
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 1 132539-06-1 4585
9
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
10
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 84057-84-1 3878
11
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 94-09-7, 1994-09-7 2337
12
tannic acid Approved Phase 4,Phase 3,Not Applicable 1401-55-4
13
Carbamazepine Approved, Investigational Phase 4,Phase 3,Phase 1 298-46-4 2554
14
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
15
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
16
Infliximab Approved Phase 4 170277-31-3
17
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 7440-70-2 271
18
Choline Approved, Nutraceutical Phase 4 62-49-7 305
19 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Antimanic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Dopamine agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Dopamine D2 Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Serotonin 5-HT1 Receptor Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Serotonin Receptor Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Quetiapine Fumarate Phase 4,Phase 3,Phase 2,Not Applicable 111974-72-2
29 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Serotonin Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Serotonin 5-HT2 Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1
37 GABA Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Gastrointestinal Agents Phase 4,Phase 3,Phase 1
39 Diuretics, Potassium Sparing Phase 4,Phase 3,Phase 2,Phase 1
40 Antiemetics Phase 4,Phase 3,Phase 1
41 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Phase 1
42 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 1
43 Sodium Channel Blockers Phase 4,Phase 3,Phase 2,Phase 1
44 Autonomic Agents Phase 4,Phase 3,Phase 1
45 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 1
46 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
48 calcium channel blockers Phase 4,Phase 3,Phase 2,Phase 1
49 Hormones Phase 4,Phase 3,Phase 2,Phase 1
50 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 220)
# Name Status NCT ID Phase Drugs
1 Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients Unknown status NCT01710163 Phase 4 Lithium;Aripiprazole
2 Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
3 Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder Unknown status NCT00608075 Phase 4 lithium;Lithium
4 Efficacy and Safety of Utapine vs. Seroquel in Patients With Bipolar Mania Unknown status NCT01043679 Phase 4 Utapine;Seroquel
5 Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder Completed NCT00034580 Phase 4 olanzapine;risperidone
6 A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode Completed NCT00277212 Phase 4 Lamotrigine + Aripiprazole;Lamotrigine + Placebo
7 A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients Completed NCT00402324 Phase 4 olanzapine;placebo;divalproex
8 The Young Adult and Pediatric Bipolar Study Completed NCT00350857 Phase 4 Extended-Release Carbamazepine
9 The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder Completed NCT00044187 Phase 4 Sibutramine
10 Study in Adolescents With Schizophrenia or Bipolar Disorder Completed NCT00982020 Phase 4 Olanzapine
11 Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder Completed NCT00050206 Phase 4 Olanzapine;Placebo
12 Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder Completed NCT00178061 Phase 4
13 Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder Completed NCT00094549 Phase 4 olanzapine;divalproex sodium;placebo
14 Citicoline for Bipolar 1 Disorder and Cocaine Dependence Completed NCT00619723 Phase 4 Citicoline;Placebo
15 Efficacy of Combined Treatment for Young Bipolar I Disorder Completed NCT00976794 Phase 4 lithium plus carbamazepine;lithium plus valproate
16 Olanzapine Plus Carbamazepine in the Treatment of Bipolar I Mania Completed NCT00190892 Phase 4 olanzapine;carbamazepine
17 Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder Completed NCT00139594 Phase 4 licarbazepine
18 A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania Completed NCT00261443 Phase 4 Lithium or Valproate with placebo (PBO);Lithium or Valproate with Aripiprazole
19 A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression Completed NCT00844857 Phase 4 Olanzapine Fluoxetine Combination (OFC);Placebo
20 Sequential Multiple Assignment Treatment for Bipolar Disorder Completed NCT01588457 Phase 4 Lithium/Lithium Carbonate;Divalproex;Lamotrigine;Quetiapine
21 ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness Completed NCT00484471 Phase 4 aripiprazole;valproate;placebo
22 Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder Completed NCT00672490 Phase 4 Quetiapine Fumarate;Lithium
23 A Study of Infliximab for Treatment Resistant Major Depression Completed NCT00463580 Phase 4 Infliximab;Placebo
24 DB/Maintenance of Equetro (Carbamazepine) in Children With Acute Manic or Mixed Bipolar 1 Disorder Recruiting NCT02623504 Phase 4 Carbamazepine;Placebo
25 DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole Not yet recruiting NCT03881449 Phase 4
26 A Trial to Measure the Difference in All-cause Hospitalizations for Patients Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder Terminated NCT03643159 Phase 4 aripiprazole or other oral antipsychotics
27 Seroquel in Acute Mania: Study to Investigate if Valproate Add-On Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients Terminated NCT00139074 Phase 4 Quetiapine fumarate;sodium valproate
28 Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania Withdrawn NCT01495156 Phase 4 Lithium treatment in combination with a SGA (Second Generation Antipsychotic);Placebo/Adjunctive SGA treatment
29 Safety and Efficacy Study of Lithium in Bipolar Disorder Unknown status NCT00422331 Phase 3 Lithium Carbonate Capsule
30 Lithium Versus Divalproex for Treating Pediatric Bipolar Disorder Unknown status NCT00221429 Phase 3 lithium sodium divalproex
31 Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder Completed NCT01059539 Phase 3 cariprazine
32 A Study for the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents Completed NCT00195780 Phase 3 Divalproex Sodium (Depakote ER)
33 Safety and Efficacy of Cariprazine for Bipolar I Disorder Completed NCT01058668 Phase 3 Cariprazine;Placebo
34 A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder. Completed NCT01986114 Phase 3 SM-13496 (lurasidone HCl)
35 A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder Completed NCT00490971 Phase 3 Olanzapine;Paliperidone ER;Placebo
36 Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder Completed NCT00107731 Phase 3 quetiapine fumarate;lithium;divalproex
37 Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder Completed NCT00227305 Phase 3 quetiapine fumarate
38 This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296 Completed NCT01575561 Phase 3 Lurasidone
39 An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder Completed NCT00238485 Phase 3 Licarbazepine
40 Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, Depressed Completed NCT00618748 Phase 3 Olanzapine
41 A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder Completed NCT03259555 Phase 3 Brexpiprazole;Placebo
42 A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder Completed NCT03257865 Phase 3 Brexpiprazole;Placebo
43 Lurasidone and Cognition in Bipolar I Disorder Completed NCT02147379 Phase 3 Lurasidone
44 Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder Completed NCT01305408 Phase 3 Armodafinil;Placebo
45 Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder Completed NCT01072630 Phase 3 Armodafinil;Placebo
46 A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder Completed NCT01072929 Phase 3 Armodafinil;Placebo
47 Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder Completed NCT00129220 Phase 3 olanzapine;haloperidol;placebo
48 Safety and Tolerability of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed) Completed NCT00265330 Phase 3 Ziprasidone oral capsules
49 Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients Completed NCT01567527 Phase 3 Intramuscular (IM) Depot Aripiprazole;Intramuscular (IM) Depot Placebo
50 An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder. Completed NCT00228059 Phase 3 Licarbazepine

Search NIH Clinical Center for Bipolar I Disorder

Genetic Tests for Bipolar I Disorder

Anatomical Context for Bipolar I Disorder

MalaCards organs/tissues related to Bipolar I Disorder:

42
Brain, Amygdala, Cortex, Testes, Eye, Bone, Thyroid

Publications for Bipolar I Disorder

Articles related to Bipolar I Disorder:

(show top 50) (show all 795)
# Title Authors Year
1
GAD1 gene polymorphisms are associated with bipolar I disorder and with blood homovanillic acid levels but not with plasma GABA levels. ( 30625343 )
2019
2
Combined Processing of Facial and Vocal Emotion in Remitted Patients With Bipolar I Disorder. ( 30729905 )
2019
3
Lithium for the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled Discontinuation Study. ( 30738555 )
2019
4
Comorbidity of Bipolar-I Disorder and Conduct Disorder: A Familial Risk Analysis. ( 30758064 )
2019
5
Pathways to Care for Patients with Bipolar-I Disorder: An Exploratory Study from a Tertiary Care Centre of North India. ( 30783311 )
2019
6
Risperidone adjunctive therapy duration in the maintenance treatment of bipolar I disorder: A post hoc analysis. ( 30795492 )
2019
7
47 Sustained Functional Recovery and Symptom Remission After Maintenance Treatment with Aripiprazole Once-Monthly for Patients with Bipolar I Disorder. ( 30859975 )
2019
8
Association between solar insolation and a history of suicide attempts in bipolar I disorder. ( 30878786 )
2019
9
Cognitive variability in bipolar I disorder: A cluster-analytic approach informed by resting-state data. ( 30914304 )
2019
10
Inflammatory cytokines and cognitive functioning in early-stage bipolar I disorder. ( 30447566 )
2019
11
The association between mood state and chronobiological characteristics in bipolar I disorder: a naturalistic, variable cluster analysis-based study. ( 29457195 )
2018
12
Can Residual Symptoms During Inter-Episode Period after Partial Remission in Bipolar I Disorder Have Cyclic Patterns with Specific Frequencies? ( 29486550 )
2018
13
Lack of emotional gaze preferences using eye-tracking in remitted bipolar I disorder. ( 29968068 )
2018
14
Budget impact analysis of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA. ( 29694243 )
2018
15
Quetiapine Related Acute Paralytic Ileus in a Bipolar I Disorder Patient with Successful Low Dose Amisulpride Substitution: A Case Report. ( 29739140 )
2018
16
The effects of psychoeducational family intervention on coping strategies of relatives of patients with bipolar I disorder: results from a controlled, real-world, multicentric study. ( 29692615 )
2018
17
Cognitive functioning in first episode bipolar I disorder patients with and without history of psychosis. ( 29055258 )
2018
18
Anterior Cingulate Cortex Glutamatergic Metabolites and Mood Stabilizers in Euthymic Bipolar I Disorder Patients: A Proton Magnetic Resonance Spectroscopy Study. ( 29789269 )
2018
19
Psychosocial functioning in patients with psychotic and non-psychotic bipolar I disorder. A comparative study with individuals with schizophrenia. ( 29316520 )
2018
20
Cardiometabolic risks and omega-3 index in recent-onset bipolar I disorder. ( 29479787 )
2018
21
Influence of age at onset on the course and outcome of bipolar I disorder: Findings from a retrospective study. ( 29494947 )
2018
22
Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients. ( 29391801 )
2018
23
An overview of pharmacotherapy for bipolar I disorder. ( 29361880 )
2018
24
The association between social skills deficits and family history of mood disorder in bipolar I disorder. ( 29590265 )
2018
25
Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400A mg in bipolar I disorder in the USA. ( 29694244 )
2018
26
Could schizoaffective disorder, schizophrenia and bipolar I disorder be distinguishable using cognitive profiles? ( 29852325 )
2018
27
No neuronal autoantibodies detected in plasma of patients with a bipolar I disorder. ( 29136601 )
2018
28
Perception of inpatients following remission of a manic episode in bipolar I disorder on a group-based Psychoeducation program: a qualitative study. ( 29378562 )
2018
29
Predictors and outcomes of somatization in bipolar I disorder: A latent class mixture modeling approach. ( 29174742 )
2018
30
Comparison of salivary testosterone levels in different phases of bipolar I disorder and control group. ( 29887899 )
2018
31
Mixed Features in Bipolar I Disorder and the Effect of Lithium on Suicide. ( 29301424 )
2018
32
Psychoeducation for psychiatric inpatients following remission of a manic episode in bipolar I disorder: A randomized controlled trial. ( 29578271 )
2018
33
Association of intracortical myelin and cognitive function in bipolar I disorder. ( 29536533 )
2018
34
Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder. ( 29174738 )
2018
35
Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study. ( 29886522 )
2018
36
Secular trends in the age at onset of bipolar I disorder - Support for birth cohort effects from interational, multi-centre clinical observational studies. ( 29734127 )
2018
37
Quality of life in stabilized outpatients with bipolar I disorder: Associations with resilience, internalized stigma, and residual symptoms. ( 29909303 )
2018
38
Aripiprazole Long-Acting Injectable for Maintenance Treatment of Bipolar I Disorder in Adults. ( 29341822 )
2018
39
Double trouble: weekend sleep changes are associated with increased impulsivity among adolescents with bipolar I disorder. ( 29781205 )
2018
40
Assessment of cognitive functions in bipolar I disorder: A 1-year naturalistic follow-up study. ( 29314557 )
2018
41
Transitioning from Bipolar II to Bipolar I Disorder in Late Life: Implications for Practice. ( 29725185 )
2018
42
Glycogen synthase kinase-3I^ activity and cognitive functioning in patients with bipolar I disorder. ( 29433844 )
2018
43
Differences between unipolar mania and bipolar-I disorder: Evidence from nine epidemiological studies. ( 30475430 )
2018
44
Neurocognition and functional outcome in patients with psychotic, non-psychotic bipolar I disorder, and schizophrenia. A five-year follow-up. ( 30500572 )
2018
45
Hospitalization risk factors in antipsychotic-treated schizophrenia, bipolar I disorder or major depressive disorder. ( 30556736 )
2018
46
Association between childhood trauma exposure and pro-inflammatory cytokines in schizophrenia and bipolar-I disorder. ( 30560764 )
2018
47
Genetic Variations of DAOA (rs947267 and rs3918342) and COMT Genes (rs165599 and rs4680) in Schizophrenia and Bipolar I Disorder. ( 30719257 )
2018
48
The economic burden of bipolar I disorder in the United States in 2015. ( 28961441 )
2018
49
Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder. ( 29017067 )
2018
50
Regional cortical thinning in young adults with schizophrenia but not psychotic or non-psychotic bipolar I disorder. ( 29992455 )
2018

Variations for Bipolar I Disorder

Expression for Bipolar I Disorder

Search GEO for disease gene expression data for Bipolar I Disorder.

Pathways for Bipolar I Disorder

GO Terms for Bipolar I Disorder

Cellular components related to Bipolar I Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.85 DRD2 HTR1A HTR2A HTR2C NRG1 SLC6A4
2 dendritic spine GO:0043197 9.58 COMT DRD2 DTNBP1
3 glutamatergic synapse GO:0098978 9.55 DRD2 DTNBP1 GRID1 HTR2A NRG1
4 integral component of presynaptic membrane GO:0099056 9.5 DRD2 HTR2A SLC6A4
5 integral component of postsynaptic membrane GO:0099055 9.43 DRD2 HTR2A SLC6A4
6 dendrite GO:0030425 9.43 BDNF COMT DRD2 HTR1A HTR2A HTR2C
7 axon GO:0030424 9.1 BDNF COMT DRD2 DTNBP1 HTR2A NRG1

Biological processes related to Bipolar I Disorder according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 locomotory behavior GO:0007626 9.72 DRD2 HTR2C NRG1
2 response to drug GO:0042493 9.72 COMT DRD2 HTR2A HTR2C SLC6A4
3 circadian rhythm GO:0007623 9.71 EGR3 PER3 SLC6A4
4 memory GO:0007613 9.7 BDNF HTR2A SLC6A4
5 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.67 HTR1A HTR2A HTR2C
6 modulation of chemical synaptic transmission GO:0050804 9.65 BDNF DRD2 GRID1
7 synapse assembly GO:0007416 9.63 BDNF DRD2 NRG1
8 feeding behavior GO:0007631 9.62 DRD2 HTR2C
9 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.62 HTR1A HTR2A
10 regulation of dopamine secretion GO:0014059 9.61 DTNBP1 HTR2A
11 behavioral fear response GO:0001662 9.61 HTR1A HTR2C
12 regulation of synaptic vesicle exocytosis GO:2000300 9.61 DRD2 DTNBP1 HTR2A
13 activation of phospholipase C activity GO:0007202 9.6 BDNF HTR2A
14 response to light stimulus GO:0009416 9.59 DRD2 PER3
15 temperature homeostasis GO:0001659 9.58 DRD2 HTR2A
16 behavioral response to cocaine GO:0048148 9.58 DRD2 HTR2A
17 vasoconstriction GO:0042310 9.57 HTR1A SLC6A4
18 dopamine metabolic process GO:0042417 9.56 COMT DRD2
19 release of sequestered calcium ion into cytosol GO:0051209 9.54 DRD2 HTR2A HTR2C
20 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.51 DRD2 HTR2A
21 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.4 HTR2A HTR2C
22 peripheral nervous system development GO:0007422 9.33 BDNF EGR3 NRG1
23 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.26 HTR2A HTR2C
24 behavior GO:0007610 9.13 HTR1A HTR2A HTR2C
25 serotonin receptor signaling pathway GO:0007210 8.8 HTR1A HTR2A HTR2C

Molecular functions related to Bipolar I Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.5 DRD2 HTR2A HTR2C
2 neurotransmitter receptor activity GO:0030594 9.43 HTR1A HTR2A HTR2C
3 G protein-coupled serotonin receptor activity GO:0004993 9.33 HTR1A HTR2A HTR2C
4 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 8.96 HTR2A HTR2C
5 serotonin binding GO:0051378 8.92 HTR1A HTR2A HTR2C SLC6A4

Sources for Bipolar I Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....